CN110256541A - Polypeptide and its application of engler's disease serum antibody are cloned in a kind of detection - Google Patents
Polypeptide and its application of engler's disease serum antibody are cloned in a kind of detection Download PDFInfo
- Publication number
- CN110256541A CN110256541A CN201910407625.2A CN201910407625A CN110256541A CN 110256541 A CN110256541 A CN 110256541A CN 201910407625 A CN201910407625 A CN 201910407625A CN 110256541 A CN110256541 A CN 110256541A
- Authority
- CN
- China
- Prior art keywords
- engler
- polypeptide
- clone
- kit
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/355—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Nocardia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/355—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Nocardia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Abstract
The invention belongs to field of biological technology detection, polypeptide and its application of a kind of detection clone engler's disease serum antibody are disclosed.Specific polypeptide including combining clone's engler's disease serum antibody, the polypeptide are any one in SEQ ID No.1-16.Polypeptide sequence provided by the invention is significantly higher than the combination to patients of ulcerative colitis serum immune globulin or Healthy Human Serum immunoglobulin to the combination that clinical diagnosis is clone's engler patient serum.
Description
Technical field
The present invention relates to field of biological technology detection more particularly to it is a kind of detection clone engler's disease serum antibody polypeptide and
Its application in terms of detection kit.
Background technique
Inflammatory bowel disease (Inflammatory Bowel Disease, IBD), is a kind of with autoimmunity disease feature
Chronic gut inflammation disease, including clone engler disease (Crohn disease) and ulcerative colitis.The serious symptom of inflammatory bowel disease
Digestive tract function is influenced, there is pain, diarrhea, the cardinal symptoms such as hematochezia, intestinal tissue has inflammation foci, and ulcer there are intestines when serious
Road perforation.Inflammatory bowel disease is refractory more, has the characteristics of recurrent exerbation, and have the risk of canceration.Inflammatory bowel disease is common in west
Country, ascendant trend is presented in disease incidence at home in recent years.
Clone's engler's disease is a kind of chronic, recurrent exerbation enteron aisle disease, and site of pathological change can be from oral cavity to anus
Any part of entire gastrointestinal tract, advanced stage ileum and colon are impacted most regions.This disease be usually presented with abdominal pain,
Energy loss, weight loss, night sweat, canker sore and arthralgia etc..The mechanism and the cause of disease for cloning the morbidity of engler's disease are always not
It is clear, it is relevant with hereditary, immune, intestinal microecology etc..
Diagnosis for cloning engler's disease relies primarily on clinical manifestation, laboratory conventional detection, radioexmination, interior at present
The means such as mirror and pathological examination, wherein scope and pathological examination are clinical main diagnosis basis.Due to non-IBD inflammatory bowel
Disease is similar to many clinical manifestations and pathological change of IBD, and scope and pathological examination are often difficult to make a definite diagnosis, and scope and pathology
It checks complicated for operation, belongs to invasive, therefore have some limitations.And to the treatment method of non-IBD inflammatory bowel disease and IBD
Difference, prognosis is also different, so more special method is needed to be identified.In addition, in IBD ulcerative colitis with
Engler's disease is cloned, there is also certain identification difficulties for methods for clinical diagnosis at present.
In consideration of it, establishing simple, noninvasive, economic, quick, the inexpensive method of one kind to carry out the diagnosis tool of clone's engler's disease
There is important clinical value.
Summary of the invention
The purpose of the present invention is to provide the polypeptides and its kit of a kind of detection clone engler's disease serum antibody, wherein wrapping
Include the polypeptide of specific binding clone's engler's disease serum antibody.Polypeptide provided by the invention is clone's engler's disease to clinical diagnosis
The combination of patients serum is significantly higher than to patients of ulcerative colitis serum immune globulin or Healthy Human Serum immunoglobulin
Combination, and kit provided by the invention detection clone engler's disease serum antibody in terms of have it is simple, noninvasive, economical, fast
Feature fast, inexpensive, sensitive, specificity is high.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The present invention provides a kind of polypeptide of detection clone engler's disease serum antibody, the polypeptide includes in SEQ ID No.1-16
Shown in one of amino acid sequence or a variety of.
Preferably, the polypeptide is one of amino acid sequence shown in SEQ ID No.2-16 or a variety of amino acid
Sequence
Preferably, the clone engler disease serum antibody includes igA antibody and/or immunoglobulin g antibody.
A kind of kit of detection clone engler's disease serum antibody, including the polypeptide.
Preferably, the kit is enzyme linked immunological kit, immunoturbidimetry kit, colloidal gold method kit or exempts from
Epidemic disease chemoluminescence method kit.
Preferably, the enzyme linked immunological kit further includes ELISA Plate, PBST washing buffer, sample diluting liquid, enzyme mark
Secondary antibody, PBST washing buffer, TMB developing solution and sulfuric acid terminate liquid.
Polypeptide provided by the invention can not only be in conjunction with the antibody specificity of clone's engler patient serum, the polypeptide sequence
Column have special and stable β-corner structure, and the polypeptide is located at the marginal position of tertiary structure, can be realized stable knot
It closes, sensibility is high.Polypeptide sequence provided by the invention is significantly high to the combination that clinical diagnosis is clone's engler patient serum
In the combination to patients of ulcerative colitis serum immune globulin or Healthy Human Serum immunoglobulin.
And the present invention establishes detection clone's engler patient serum antibody quantitative detecting reagent and clone's engler's sufferer
The joint detection of person's Serum Antibody Detection reagent (S. cervisiae polysaccharide antigen and coli flagellum PROTEIN C Bir antigen)
Method, the diagnosis for cloning engler's disease have more clinical meaning.
Detailed description of the invention
Fig. 1 promise card bacterium MCE albumen and mycobacteria MFS protein sequence comparison chart.
The standard curve of kit detection clone's engler's disease serum antibody standard items Fig. 2 of the invention.
Specific embodiment
It in order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below will be in the embodiment of the present invention
Scheme carry out clear and complete description.The person that is not specified actual conditions in embodiment, according to normal conditions or manufacturer suggests
Condition carries out.Agents useful for same or the not well-known production firm person of instrument are the conventional products that can be obtained by commercially available purchase.
Embodiment 1
We are to mycobacterium transport protein (major facilitator superfamily, MFS) and promise card bacterium mammal
Sequence analysis is carried out into albumen (Mammalian cell entry protein, MCE).Sequence alignment according to figure 1
The results show that promise card bacterium MCE albumen and mycobacterium MFS albumen have one section of conservative sequence, and pass through artificial synthesized side
Method has obtained the amino acid sequence of this section of conserved region: IRGLFPN, which is conventional solid-phase synthesis.We
Meet this special stable structure of β-corner by this 7 peptide that sequence alignment and structure prediction result obtain
1. amino acid polarity check result of table
Polarity check is carried out to 7 peptide of conserved sequence of promise card bacterium MCE albumen and mycobacteria MFS albumen.
Table 1a promise card bacterium MCE albumen MIRGLFPN
| M | I | R | G | L | F | P | N |
| Methionine | Isoleucine | Arginine | Glycine | Leucine | Phenylalanine | Proline | Asparagine |
| Polarity, neutrality | It is nonpolar, hydrophobic | Alkalinity | It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | Polarity, neutrality |
Table 1b mycobacteria MFS albumen LIRGLFPN
| L | I | R | G | L | F | P | N |
| Leucine | Isoleucine | Arginine | Glycine | Leucine | Phenylalanine | Proline | Asparagine |
| It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | Alkalinity | It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | It is nonpolar, hydrophobic | Polarity, neutrality |
According to promise card bacterium MCE albumen and mycobacteria MFS albumen Tertiary structure predictions the results show that the position of 7 peptides is located at edge
Random coil position.50 amino acid of MCE albumen and MFS albumen near 7 peptides are subjected to secondary structure prediction, as a result
It was found that having antibody combining site near 7 peptides.
According to the above results, inventor is to have the polypeptide of clone's engler's disease serum antibody specific bond as fixation
Phase constructs the kit for capableing of selective enumeration method clone's engler patient serum antibody, realizes to clone engler patient
The qualitative and quantitative detection of Serum Antibody.
Embodiment 2 prepares enzyme linked immunological kit
(1) preparation of reagent:
Standard items: the standard solution of 6 various concentrations, standard items A is 100U/mL, standard items B is 50U/mL, standard items C is
25U/mL, standard items D are 12.5U/mL, standard items E is 6.25U/mL, standard items F is 0U/mL.
Reference substance: the positive reference substance that configuration concentration is 50-60 U/ml and the negative control that concentration is 5-10 U/ml are needed
Product.
Sample diluting liquid: according to a certain percentage by PB buffer (PH=6.0 ± 0.2), NaCl, NH of 0.2M4Cl, junket egg
White, 20%Tween-20, Triton-X100, inactivated fetal bovine serum are substantially soluble in water.
1*PBST washing buffer: pH value 7.4, including the Na of 80mmol/L2HPO4, 20mmol/L KH2PO4、
The NaCl of KCl, 1400mmol/L of 100mmol/L, the Tween-20 that volume fraction is 0.05%.
TMB developing solution: substrate develops the color A liquid: sodium acetate 13.6g, citric acid 1.6g, 30% hydrogen peroxide 0.3ml, distilled water add
To 500ml；Substrate colour developing B liquid: disodium ethylene diamine tetraacetate 0.2g, citric acid 0.95g, glycerol 50ml take 0.15g TMB to be dissolved in
In 30ml DMSO, distilled water adds to 500ml, in use, take substrate colour developing A liquid and substrate develop the color B liquid mix in equal volume to get
TMB developing solution.
Sulfuric acid terminate liquid: configuration concentration is the dilution heat of sulfuric acid of 2M.
ELIAS secondary antibody: horseradish peroxidase-labeled goat anti-human igg and/or IgA antibody are used.
Sealing plate film: for resistance to think of PCR sealing plate film.
(2) it is coated with polypeptide ELISA Plate:
The coating buffer containing polypeptide is prepared, 100 μ L are added in every hole of 96 hole elisa Plates, set 4 DEG C, 16~18 h.
Coating buffer is discarded, 300 μ 1 × cleaning solutions of L are added in every hole, get rid of solution in hole after standing 2 min and pat dry；Every hole
200 μ L confining liquids are added, stand 1.5h in 25 DEG C of constant incubators；After discarding confining liquid, 300 1 × cleanings of μ L are added in every hole
Liquid gets rid of liquid in hole after standing 2 minutes and pats dry；Set dry 5h in 25 DEG C of air dry ovens.
(3) it dispenses: taking 1*PBST washing buffer, standard items, reference substance, sample diluting liquid, ELIAS secondary antibody, TMB colour developing
Liquid, sulfuric acid terminate liquid and be coated with polypeptide ELISA Plate independently pack to get.
3 test sample of embodiment and drafting standard curve
The enzyme linked immunological kit prepared with embodiment 1
(1) it is loaded: 100 μ L various concentration standard items and patients serum's sample being added in microwell plate.The concentration of standard items is distinguished
For 100U/mL, 50U/mL, 25U/mL, 12.5U/mL, 6.25U/mL, 0U/mL.
(2) be incubated for: with after sealing plate film sealing plate in room temperature (20 DEG C -28 DEG C) stationary incubation 30 minutes.
(3) it washs: taking sealing plate film off, discard liquid in hole, cleaning solution, every hole 300uL, after standing 2min are added after drying
Liquid in hole is discarded, is repeated 3 times.
(4) add ELIAS secondary antibody: the 100 μ L of ELIAS secondary antibody liquid diluted is added in every hole.
(5) it is incubated for: operating with (4).
(6) it washs: operating with (5).
(7) it develops the color: colour developing A liquid and B liquid being mixed in 1:1 ratio, obtain TMB developing solution, 100 μ L, room temperature is added in every hole
It is protected from light standing 15 minutes.
(8) terminate: 50 μ L of terminate liquid is added in every hole, and light shake is mixed to terminate reaction.In patients serum's sample well color by
Blue becomes yellow.
(9) it measures: sequentially measuring the OD value in each hole at 450/630 nm of 450 nm of Single wavelength or dual wavelength.
According to the concentration of standard items: 100U/mL, 50U/mL, 25U/mL, 12.5U/mL, 6.25U/mL, 0U/mL.It calculates every
The average value of a concentration standards duplicate hole OD value, with the concentration (U/mL) of standard items for abscissa, corresponding OD value is vertical sits
Mark draws standard curve using Data Analysis Software (Origin 8), as shown in Figure 2.
The serum of the healthy population largely without related disease is detected using the method for the present invention and product completion.Institute
Obtained sample concentration mean value+3SD is that positive cutoff value (cut-off value) is 25U/ml.
The specific detection of 4 polypeptide antigen of embodiment
7 artificial synthesized peptides are fixed phase, have detected 129 clinical diagnosises as clone's engler's disease, 130 ulcerative colitis
With 200 normal human serum samples.
Determine in clone's engler's disease and patients of ulcerative colitis serum with the presence or absence of the side in conjunction with peptide fragment immunoglobulin
Method is first to calculate normal population serum sample according to the measurement to normal human serum sample and be fixed on peptide fragment in porous plate hole
Immunoglobulin basic value, determine whether the amount of the antibody in patients serum in conjunction with peptide fragment significant further according to basic value
Increase.
In three groups of serum samples of experiment, which is that clone's engler patient serum is anti-
Body.Testing result finds this polypeptide fragment energy Selective recognition clone's engler patient sero-immunity for containing 7 amino acid
Globulin A and immunoglobulin G, and be not the immune ball in ulcerative colitis or normal human serum sample with clinical diagnosis
Protein binding.
Sensibility, the specificity experiments result of 2 polypeptide antigen of table
Embodiment 5 establishes polypeptide antigen and the joint-detection of ASCA
Polypeptide is clone's engler's disease sample and 200 normal human serum samples with 129 clinical diagnosises of ASCA joint-detection.
Specific method is: polypeptide being detected respectively with ASCA, finally combine sentencing according to the data result of the two
Fixed, as long as there is one can be determined as Crohn's disease beyond decision content in the two, the purpose is to improve Crohn's disease detection
Sensibility.
The method of the joint-detection, which can also be, is prepared into combined detection kit, and the combined detection kit includes more
Peptide and antigen, the antigen are S. cervisiae polysaccharide antigen and coli flagellum PROTEIN C Bir antigen.
3 polypeptide of table and ASCA joint detection results
By testing result it is known that the specific highest of polypeptide provided by the invention, the joint-detection of polypeptide and ASCA are shown
The sensibility for improving clinical diagnosis is write, this has more clinical meaning for cloning the diagnosis of engler's disease.
The above is only present pre-ferred embodiments, is not intended to limit the scope of the present invention, therefore
Any subtle modifications, equivalent variations and modifications to the above embodiments according to the technical essence of the invention, still belong to
In the range of technical solution of the present invention.
Sequence table
<110>Shanxi Rui Hao Biotechnology Co., Ltd
<120>a kind of polypeptide of detection clone engler's disease serum antibody and its application
<141> 2019-05-15
<160> 16
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7
<212> PRT
<213>artificial sequence ()
<400> 1
Ile Arg Gly Leu Phe Pro Asn
1 5
<210> 2
<211> 7
<212> PRT
<213>artificial sequence ()
<400> 2
Ile Arg Gly Thr Phe Ala Asn
1 5
<210> 3
<211> 8
<212> PRT
<213>artificial sequence ()
<400> 3
Met Ile Arg Gly Leu Phe Pro Asn
1 5
<210> 4
<211> 8
<212> PRT
<213>artificial sequence ()
<400> 4
Ile Arg Gly Leu Phe Pro Asn Pro
1 5
<210> 5
<211> 9
<212> PRT
<213>artificial sequence ()
<400> 5
Ala Met Ile Arg Gly Leu Phe Pro Asn
1 5
<210> 6
<211> 9
<212> PRT
<213>artificial sequence ()
<400> 6
Ile Arg Gly Leu Phe Pro Asn Pro Gln
1 5
<210> 7
<211> 10
<212> PRT
<213>artificial sequence ()
<400> 7
Asp Ala Met Ile Arg Gly Leu Phe Pro Asn
1 5 10
<210> 8
<211> 10
<212> PRT
<213>artificial sequence ()
<400> 8
Ile Arg Gly Leu Phe Pro Asn Pro Gln Glu
1 5 10
<210> 9
<211> 8
<212> PRT
<213>artificial sequence ()
<400> 9
Leu Ile Arg Gly Leu Phe Pro Asn
1 5
<210> 10
<211> 8
<212> PRT
<213>artificial sequence ()
<400> 10
Ile Arg Gly Leu Phe Pro Asn Gly
1 5
<210> 11
<211> 9
<212> PRT
<213>artificial sequence ()
<400> 11
Ala Leu Ile Arg Gly Leu Phe Pro Asn
1 5
<210> 12
<211> 9
<212> PRT
<213>artificial sequence ()
<400> 12
Ile Arg Gly Leu Phe Pro Asn Gly Arg
1 5
<210> 13
<211> 10
<212> PRT
<213>artificial sequence ()
<400> 13
Leu Ala Leu Ile Arg Gly Leu Phe Pro Asn
1 5 10
<210> 14
<211> 10
<212> PRT
<213>artificial sequence ()
<400> 14
Ile Arg Gly Leu Phe Pro Asn Gly Arg Glu
1 5 10
<210> 15
<211> 14
<212> PRT
<213>artificial sequence ()
<400> 15
Ile Arg Gly Leu Phe Pro Asn Ile Arg Gly Leu Phe Pro Asn
1 5 10
<210> 16
<211> 21
<212> PRT
<213>artificial sequence ()
<400> 16
Ile Arg Gly Leu Phe Pro Asn Ile Arg Gly Leu Phe Pro Asn Ile Arg
1 5 10 15
Gly Leu Phe Pro Asn
20
Claims (6)
1. a kind of polypeptide of detection clone engler's disease serum antibody, which is characterized in that the polypeptide includes SEQ ID No.1-16
Shown in one of amino acid sequence or a variety of.
2. the polypeptide of detection clone engler's disease serum antibody as described in claim 1, which is characterized in that the polypeptide is SEQ
One of amino acid sequence in ID No.2-16 is a variety of.
3. the polypeptide of detection clone engler's disease serum antibody as described in claim 1, which is characterized in that the clone engler disease
Serum antibody includes igA antibody and/or immunoglobulin g antibody.
4. a kind of kit of detection clone engler's disease serum antibody, which is characterized in that including claim 1-3 any one institute
The polypeptide stated.
5. the kit of detection clone engler's disease serum antibody as claimed in claim 4, which is characterized in that the kit is
Enzyme linked immunological kit, immunoturbidimetry kit, colloidal gold method kit or immunochemiluminescence method kit.
6. the kit of detection clone engler's disease serum antibody as claimed in claim 5, which is characterized in that the enzyme linked immunological
Kit further includes ELISA Plate, PBST washing buffer, sample diluting liquid, ELIAS secondary antibody, PBST washing buffer, TMB colour developing
Liquid and sulfuric acid terminate liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910407625.2A CN110256541A (en) | 2019-05-15 | 2019-05-15 | Polypeptide and its application of engler's disease serum antibody are cloned in a kind of detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910407625.2A CN110256541A (en) | 2019-05-15 | 2019-05-15 | Polypeptide and its application of engler's disease serum antibody are cloned in a kind of detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110256541A true CN110256541A (en) | 2019-09-20 |
Family
ID=67914745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910407625.2A Pending CN110256541A (en) | 2019-05-15 | 2019-05-15 | Polypeptide and its application of engler's disease serum antibody are cloned in a kind of detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110256541A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115746112A (en) * | 2022-07-14 | 2023-03-07 | 山东第一医科大学附属省立医院(山东省立医院) | Nocardia specific antigen protein, serological diagnosis kit and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1505637A (en) * | 2001-04-24 | 2004-06-16 | ��V��ҩ��ʽ���� | Crohn's disease antibody-binding peptide and method of examining crohn's disease |
| WO2006013661A1 (en) * | 2004-08-05 | 2006-02-09 | Toagosei Co., Ltd. | Crohn’s disease antibody epitope peptide and reagent for testing crohn’s disease |
| AU2012207041A1 (en) * | 2005-02-18 | 2012-08-16 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli |
-
2019
- 2019-05-15 CN CN201910407625.2A patent/CN110256541A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1505637A (en) * | 2001-04-24 | 2004-06-16 | ��V��ҩ��ʽ���� | Crohn's disease antibody-binding peptide and method of examining crohn's disease |
| WO2006013661A1 (en) * | 2004-08-05 | 2006-02-09 | Toagosei Co., Ltd. | Crohn’s disease antibody epitope peptide and reagent for testing crohn’s disease |
| AU2012207041A1 (en) * | 2005-02-18 | 2012-08-16 | J. Craig Venter Institute, Inc. | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115746112A (en) * | 2022-07-14 | 2023-03-07 | 山东第一医科大学附属省立医院(山东省立医院) | Nocardia specific antigen protein, serological diagnosis kit and application thereof |
| CN115746112B (en) * | 2022-07-14 | 2023-10-13 | 山东第一医科大学附属省立医院(山东省立医院) | Nocardia specific antigen protein, serological diagnosis kit and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106370856B (en) | The urine protein marker of pulmonary fibrosis and its purposes in diagnosis and prognosis | |
| KR102228185B1 (en) | An improved assay for the diagnosis of peanut allergy | |
| CN109307776A (en) | A kind of gastrin 17 detection kit of improvement | |
| US11892457B2 (en) | Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis | |
| KR20170010005A (en) | Antisecretory factor complex assay | |
| NO303852B1 (en) | Procedure for detecting analyte variants, as well as kits for performing the method | |
| CN110256541A (en) | Polypeptide and its application of engler's disease serum antibody are cloned in a kind of detection | |
| CN111796090B (en) | Time-resolved fluorescence immunochromatographic assay test strip for echinococcosis granulosus of cattle and preparation method thereof | |
| CN110261615A (en) | Cystic echinococcosis diagnostic kit and its application | |
| JP4104665B2 (en) | H. pylori diagnostic agent | |
| CN105606803B (en) | The latex enhancing immune turbidimetry kit of helicobacter pylori antibody content | |
| CN109374879A (en) | Mixed with the detection kit and its detection method of milk elements in a kind of sheep cream and sheep milk powder | |
| RU2573985C2 (en) | Using prosomatostatin in diagnostics | |
| JP2000515854A (en) | Method for measuring the presence of brain protein S-100 | |
| ES2385455A1 (en) | Determination of levels of immunogenic gluten peptides in human samples | |
| CN106501532B (en) | It is a kind of for detecting the kit of gastrin 17 | |
| EP2478364B1 (en) | Detection of auto-antibodies to nuclear antigens | |
| CN104311654A (en) | CIDE3 polypeptide, preparation of antibody thereof and applications of the antibody | |
| JP7222511B2 (en) | Peptide and its use | |
| KR101391464B1 (en) | Marker for diagnosis of lung cancer comprising HPαR | |
| CN111175520A (en) | Glyphican-3 double-antibody sandwich method detection kit and detection method | |
| CN110294796A (en) | It is used to prepare polypeptide and its application of echinococcosis granulosa diagnostic reagent | |
| KR20070023448A (en) | Autoantibody of peroxiredoxin-I as a biomarker and diagnosis kit for lung cancer using the same | |
| CN109142757A (en) | A kind of brucella indirect ELISA testing kit | |
| CN102286437B (en) | Specific antigen for detecting campylobacter jejuni antibodies and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |